First Page | Document Content | |
---|---|---|
Date: 2014-12-23 02:59:47 | NLT- gruppens rekommendation till landstingen gällande abirateron (Zytiga) samt enzalutamid (Xtandi) vid metastaserad kastrationsresistent prostatacancer efter kemoterapiAdd to Reading ListSource URL: www.janusinfo.seDownload Document from Source WebsiteFile Size: 131,59 KBShare Document on Facebook |